Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Kratom Regulation topic
No spam. Unsubscribe anytime.
Retailers, veterans and industry groups urge regulation or synthetic ban, not an outright kratom prohibition
Summary
Retailers and kratom advocates testified the market primarily needs targeted controls on synthetic derivatives and consumer protections rather than a full ban; veterans and some physicians gave opposing accounts of benefit and harm.
Retailers and industry representatives told the committee that recent harms are driven not by pure kratom leaf but by concentrated or synthetic derivatives such as 7‑hydroxymitragynine (7‑OH). John Chavez of Bridge the Gap Botanicals said the plain leaf typically contains only 0.002%–0.008% 7‑OH and that the recent spike in harms comes from synthetic, concentrated products. "These pills that are being marketed and sold as advanced kratom alkaloids...one of these tablets would be equivalent to one full kilogram of this raw leaf," Chavez said.
Doug Ball of Jackson's Food Stores said the chain sells kratom in a small number of Idaho locations and supports restrictions and safeguards but opposes prohibition: "We support the restrictions, but we do not support the prohibition on that." Veterans and other consumers described daily therapeutic use: Sean Lepper, a medically retired veteran, said kratom helped him manage pain after multiple surgeries and opposed a ban, and Mason Mollett said kratom "saved my life" as an alternative to narcotics.
Industry advocates including Kurt Bramble of the American Kratom Association and Bob Durkin, a pharmacist and former FDA official, urged a regulatory path. Bramble cited NIDA and other research that, he said, found pure‑plant kratom did not meet federal scheduling criteria; Durkin urged a Kratom Consumer Protection Act (KCPA) model with age‑gating, labeling and enforcement, warning that criminalization would push consumers toward bad actors and adulterated products.
